|
|
|
|
Low-dose estrogen may help if breast cancer recurs
WASHINGTON - A very low dose of estrogen might help women whose breast cancer has come back after treatment, researchers reported Tuesday.Even though most treatments are aimed at stopping estrogen from fueling tumors, the researchers said after years of this...
|
|
|
Teva Announces Tentative Approval of Generic Femara(R) Tablets
- (NewsRx.com) Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis'...
|
|
|
FDA Expands Use of Approved Breast Cancer Drug
Provides oral regime for hormone positive and HER2-positive advanced breast cancer SILVER SPRING, Md., Jan.29 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to...
|
|
|
FDA Okays Drug Combo for Advanced Breast Cancer
The U.S.Food and Drug Administration (FDA) has approved the combination of the targeted therapy Tykerb (chemical name: lapatinib) and the hormonal therapy Femara (chemical name: letrozole) to treat post-menopausal women diagnosed with hormone-receptor...
|
|
|
TYKERB Approved for First-Line Breast Cancer Treatment
GlaxoSmithKline announced that the U.S.Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer. TYKERB is now...
|
|
|
Pomegranate compounds may help curb breast cancer risk
else else imgBox.style.width photo.width + else // default it to para14 if no cookie setFontSize(storyfontsize,storyfontimage) name, value, expires, path, domain, secure ) expires_date new Date( + (expires) name + + escape( value ) + ( ( expires )?+ : '' ) +...
|
|
|
Approval Expanded for Breast Cancer Drug Tykerb
To include certain postmenopausal women who need hormone therapy -- Scott Roberts MONDAY, Feb.1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2...
|
|
|
Approval Expanded for Breast Cancer Drug Tykerb
MONDAY, Feb.1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy. The new approval is...
|
|
|
Lapatinib Approved for Initial Treatment of Metastatic Breast Cancer
The U.S.Food and Drug Administration (FDA) has expanded its approval of lapatinib (Tykerb) to include initial treatment of metastatic, postmenopausal breast cancer that is both HER2-positive and hormone receptor-positive. In this setting, lapatinib is...
|
|
|
GSK's TYKERB Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
GlaxoSmithKline has announced that the FDA has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.TYKERB is now indicated in combination with...
|
|
|
FDA expands use of approved breast cancer drug
(1/29) Silver Spring, Md., (January 29, 2010) -- The U.S.Food and Drug Administration approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom...
|
|
|
Expanded usage of GSK's Tykerb (lapatinib) and Novartis's Femara (letrozole) for breast cancer approved
breast cancer The U.S.and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.
|
|
|
Use of Approved Breast Cancer Drug Expanded
Provides oral regime for hormone positive and HER2-positive advanced breast cancer Washington, D.C.- infoZine - The U.S. Food and Drug Administration approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and...
|
|
|
New combination treatment gets FDA nod
RESEARCH TRIANGLE PARK, NC Feb.1, 2010 (cancerfacts.com) GlaxoSmithKline (GSK) today announced that the FDA has granted accelerated approval for a new combination regimen as a first-line treatment for women with advanced breast cancer. The new regimen...
|
|
|
2/2/10 - Teva Announces Tentative Approval of Generic Femara Tablets
Announces Tentative Approval of Generic Femara Tablets - February 2, 2010 Pharmacy Article 2/2/10 - Teva Announces Tentative Approval of Generic Femara Tablets Teva Pharmaceutical Industries Ltd.(Nasdaq: TEVA) announced that the U.S. Food and...
|
|
|
Tykerb Approved for Initial Treatment of Metastatic Breast Cancer
The U.S.Food and Drug Administration (FDA) has expanded its approval of Tykerb (lapatinib) to include initial treatment of metastatic, postmenopausal breast cancer that is both HER2-positive and hormone receptor-positive. In this setting, Tykerb is...
|
|
|
Approval Expanded for Breast Cancer Drug Tykerb
Expanded for Drug Tykerb Approval Expanded for Drug Tykerb 2/1/2010 MONDAY, Feb.1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive...
|
|
|
Pomegranate compounds may help curb breast cancer risk
Enzyme-blocking chemicals in pomegranates may reduce the risk of estrogen-fueled breast cancers, U.S.researchers said Tuesday. An acid found in pomegranates appears to block aromatase, an enzyme that converts androgen to estrogen, a hormone that plays a...
|
|
|
Approval Expanded for Breast Cancer Drug Tykerb (HealthDay)
MONDAY, Feb.1 (HealthDay News) -- The has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy. The new approval is for Tykerb's use in combination with...
|
|
|
Pomegranate compounds may help curb breast cancer risk
Enzyme-blocking chemicals in pomegranates may reduce the risk of estrogen-fueled breast cancers, U.S.researchers said Tuesday. An acid found in pomegranates appears to block aromatase, an enzyme that converts androgen to estrogen, a hormone that plays a...
|
|
|
Expansion for Glaxo's Tykerb
GlaxoSmithKline (GSK) recently announced that it has received accelerated approval from the U.S.Food and Drug Administration (FDA) for the use of Tykerb (lapatinib) as a first-line treatment for women with metastatic breast cancer in a new combination...
|
|
|
GSK's TYKERB Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer
Philadelphia,PA./PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first-line, all-oral treatment for women...
|
|
|
GSK's TYKERB(R) Receives Accelerated Approval For First-Line Combination Treatment Of Metastatic Breast Cancer
GlaxoSmithKline (NYSE: GSK) announced that the U.S.Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.
|
|
|
Approval Expanded for Breast Cancer Drug Tykerb
MONDAY, Feb.1 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy. The new approval is...
|
|
|
FDA approves Tykerb for treatment of advanced breast cancer
- The US Food and Drug Administration announced on Friday that it has approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy...
|
